Neutra Life Sciences Expands Clinical Research Footprint Through Strategic Joint Ventures

Neutra Corp's subsidiary, Neutra Life Sciences, is taking significant steps to expand its presence in the clinical research industry by securing joint venture partnerships with leading medical practices. These partnerships include collaborations with Epic Foot & Ankle Centers, Aspire Hospital Cancer Centers, and Radiant Dermatology & Aesthetics Clinic, enabling the company to diversify its clinical research offerings into podiatry, radiation oncology, and dermatology.

This strategic expansion allows Neutra Life Sciences to address the growing demand for specialized clinical research across a broader patient population. By diversifying its portfolio, the company not only strengthens its leadership in the clinical research space but also enhances its capacity to support Contract Research Organizations (CROs) and Sponsors with a wider array of clinical indications. Sydney Jim, President and CEO of Neutra Corp, highlighted the significance of this growth, noting the alignment with the increasing need for integrated clinical research solutions and the opportunity to innovate in patient care and research.

In a move to concentrate on its core life sciences and clinical research operations, Neutra Corp has also announced the divestiture of its hemp-based cannabis subsidiary, VIVIS Corporation. This decision reflects the company's strategic focus on areas with greater regulatory stability and long-term growth potential, further emphasizing its commitment to advancing healthcare through research and development.

Neutra Life Sciences' expansion into additional medical specialties is a testament to its mission of improving health outcomes through innovative research and collaboration. By building a comprehensive network of clinical research sites and delivering high-quality services to its partners, the company is poised to make a lasting impact on the field of clinical research and patient care.